Efficacy and tolerability of Fixed Dose Combination of Perindopril plus Indapamide plus Amlodipine in patients with grade II/III hypertension

Serdia Pharmaceuticals India Pvt Ltd0 个研究点目标入组 240 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1.Uncontrolled grade II and grade III hypertensive patients with a baseline blood pressure > 140/90 mmHg despite receiving any two drug therapy comprising of either ACEI, ARBs, CCBs and diuretics as individual tablets or in combination as a fixed dose combination therapy
•2.Patients of either sex
•3.With confirmed diagnosis of Grade II/ III (moderate to severe) hypertension, as per ESC 2013 guidelines

•1.Uncontrolled diabetes (Hba1c% more than 7)
•2.H/o myocardial infarction within the previous 3 months
•3.H/o cerebrovascular event within previous 3 months
•4.Uncontrolled arrhythmias
•5.H/o Heart failure
•6.Patients with class II/IV heart blocks
•7.Patients receiving beta-blockers
•8.Patients with known severe impaired renal function (serum creatinine levels 5.3 mg/dl and / or serious liver disorders)
•9.Patients unwilling to give informed consent.
•10.Patients with known history of hypersensitivity to indapamide or amlodipine or perindopril
•11.Any contraindication to Thiazide type diuretic, CCB and ACEI
•12.Pregnancy or lactation
•13.Patients with any other condition or disease, which in opinion of the investigator could preclude evaluation of response to study medication or hamper the safety of the trial participant.
•14.Patients previously enrolled in similar or any other trial in the preceding last 6 months.

发起方